The Hunt for the Next 10 Bagger

[BioSpecialist]

SNOA =Market-Cap $19 M /Cash balance $12.6 M /Shares Out 4.3 M / 17 FDA approvals received to date some of these products are in early launch phase plus additional Product launches expected within 6 months in USA and many more Approvals outside of USA // Annual Revenue on track to hit $16 million// Profitability expected in 2018 . This unknown ultra low float and brutally undervalued stock is a MUST HAVE for everyone who like Pharma stocks .GL

Sonoma Pharma (Nasdaq: SNOA)

Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55

Book Value: $4.32
Annual Revenue on track to hit $16 Million

Shares Out : 4.3 Million


Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
http://pr.report/78EFCjq0


Fact Sheet
http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

Driving to commercial EBITDAS breakeven, without dilution

Grow current product portfolio with all sales people

•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016

Launch 3 New Products –our product pipeline –one every other quarter

•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018

Regulatory Approvals and Clearances

To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.

Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.